CERS
Price
$2.31
Change
-$0.08 (-3.35%)
Updated
Oct 22 closing price
Capitalization
465.52M
11 days until earnings call
Intraday BUY SELL Signals
STXS
Price
$0.99
Change
-$0.00 (-0.00%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
99.69M
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CERS vs STXS

CERS vs STXS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CERS vs. STXS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a StrongBuy and STXS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CERS with price predictions
Oct 22, 2026

CERS's RSI Indicator ascends from oversold territory

The RSI Indicator for CERS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 23 of the 28 cases the stock moved higher. This puts the odds of a move higher at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 84 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 170 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CERS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.648) is normal, around the industry mean (2.874). P/E Ratio (-77.000) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for STXS with price predictions
Oct 22, 2026

STXS in downward trend: price dove below 50-day moving average on September 23, 2026

STXS moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 31 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STXS as a result. In 86 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for STXS turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for STXS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.143) is normal, around the industry mean (4.961). P/E Ratio (-4.145) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
CERS vs STXS: Fundamental Ratings
CERS
STXS
OUTLOOK RATING
1..100
2064
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
4988
P/E GROWTH RATING
1..100
1715
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for STXS (96). This means that CERS’s stock grew significantly faster than STXS’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

CERS's SMR Rating (94) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

CERS's Price Growth Rating (49) in the Medical Specialties industry is somewhat better than the same rating for STXS (88). This means that CERS’s stock grew somewhat faster than STXS’s over the last 12 months.

STXS's P/E Growth Rating (15) in the Medical Specialties industry is in the same range as CERS (17). This means that STXS’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSSTXS
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
N/A
Declines
ODDS (%)
Bearish Trend 15 days ago
83%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CERS: $2.39 vs. STXS: $0.99)
Brand notoriety: CERS and STXS are both not notable
CERS represents the Medical/Nursing Services, while STXS is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CERS: 89% vs. STXS: 111%
Market capitalization -- CERS: $465.52M vs. STXS: $99.69M
CERS [@Medical/Nursing Services] is valued at $465.52M. STXS’s [@Pharmaceuticals: Other] market capitalization is $99.69M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $173.92B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $156.8B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.76B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 2 FA rating(s) are green while STXS’s FA Score has 1 green FA rating(s).

  • CERS’s FA Score: 2 green, 3 red.
  • STXS’s FA Score: 1 green, 4 red.
According to our system of comparison, CERS is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while STXS’s TA Score has 3 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 4 bearish.
  • STXS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CERS is a better buy in the short-term than STXS.

Price Growth

CERS (@Medical/Nursing Services) experienced а +6.70% price change this week, while STXS (@Pharmaceuticals: Other) price change was -5.25% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.

Reported Earning Dates

CERS is expected to report earnings on Nov 02, 2026.

STXS is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Medical/Nursing Services (-1.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (+0.74% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
CERS
Daily Signal:
Gain/Loss:
STXS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-3.35%
ICUI - CERS
46%
Loosely correlated
+4.66%
UTMD - CERS
45%
Loosely correlated
+0.46%
RVTY - CERS
44%
Loosely correlated
+0.48%
ATRC - CERS
43%
Loosely correlated
+2.83%
DHR - CERS
43%
Loosely correlated
-1.76%
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
+0.31%
SMTI - STXS
38%
Loosely correlated
+0.34%
TWST - STXS
36%
Loosely correlated
-9.16%
CERS - STXS
35%
Loosely correlated
-3.35%
VCYT - STXS
33%
Poorly correlated
-0.39%
SHC - STXS
32%
Poorly correlated
+2.03%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CARL14.610.30
+2.10%
Carlsmed Inc
VERI0.57N/A
+0.30%
Veritone
OCCIM24.880.05
+0.20%
OFS Credit Company Inc
EGO32.91-2.05
-5.86%
Eldorado Gold Corp
PURR8.68-0.94
-9.77%
Hyperliquid Strategies Inc